LAB.00025 Topographic Genotyping

This policy addresses topographic genotyping (e.g., PathFinderTG platform tests such as PancraGEN, BarreGEN, and RespriDX) that integrate anatomic pathology with molecular mutational analysis. Anthem considers topographic genotyping investigational/experimental and not medically necessary; therefore, it is not covered for any indication. Noncoverage applies in all clinical scenarios, including when histology or cytology is inconclusive, and related claims (e.g., CPT/HCPCS 81479, 84999, 89240) will be denied.

"Topographic genotyping is consideredinvestigational and not medically necessaryfor all indications."

Sign up to see full coverage criteria, indications, and limitations.